NEW YORK (
) is trading at unusually high volume Wednesday with 1.4 million shares changing hands. It is currently at 4.2 times its average daily volume and trading down $2.41 (-17.4%) at $11.42 as of 4 p.m. ET.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Osiris has a market cap of $418.5 million and is part of the
industry. Shares are up 138.1% year to date as of the close of trading on Tuesday.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Therapeutics and Biosurgery. The company has a P/E ratio of 43.9, below the average drugs industry P/E ratio of 45.5 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Osiris as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. You can view the full
See all heavy volume stocks in our
or get investment ideas from our